Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

BIIB

BIOGEN INC.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 875045Held by 9 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$9.89B
Net Income FY2025
$1.29B
EPS (Basic, as reported)
$8.83
Net Margin FY2025
13.1%
ROE FY2025
7.1%
Total Equity
$18.26B
Shares Out
148M
Business description

BIOGEN INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 11,449 → 9,891 -1.6% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue11,44912,27413,45314,37813,44510,98210,1739,8369,6769,891
Cost of revenue(1,479)(1,630)(1,816)(1,955)(1,805)(2,110)(2,278)(2,533)(2,310)(2,404)
Gross profit9,97010,64411,63712,42311,639—————
Research & development——————————
Selling, general & administrative(1,948)(1,935)(2,106)(2,375)(2,504)(2,674)(2,404)(2,550)(2,404)(2,434)
Total operating expenses(6,298)(6,930)(7,564)(7,335)(8,894)(8,141)(6,582)(8,539)(7,770)(8,334)
Operating income5,1505,3445,8897,0434,5502,841————
Interest expense(260)(251)(201)(187)(222)(254)(247)(247)(250)(267)
Interest & investment income637911312042118927768125
Other income (expense), net(217)(215)1183497(1,095)108(315)(344)(306)
Pre-tax income4,9335,1295,9007,1265,0481,7453,5921,2971,9061,557
Income tax expense(1,237)(2,459)(1,426)(1,158)(992)(52)(633)(135)(274)(264)
Net income3,7032,5394,4315,8894,0011,5563,0471,1611,6321,293
EPS — basic$16.96$11.94$21.63$31.47$24.86$10.44$20.96$8.02$11.21$8.83
EPS — diluted$16.93$11.92$21.58$31.42$24.80$10.40$20.87$7.97$11.18$8.79
Shares outstanding — basic (M)218213205187161149145145146147
Shares outstanding — diluted (M)219213205187161150146146146147

Showing the latest 10 of 19 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.